Manage Diarrhea in Patients With Multiple Myeloma While Receiving Conditioning Chemotherapy for Autologous SCT
Status:
Terminated
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
For patients who receive a hematopoietic cell transplant (HCT), there is a risk of developing
a diarrhea secondary to the chemotherapy which we give. Diarrhea is usually harmless in
healthy adults; however, in transplant patients, diarrhea can result in dehydration, negative
impact on quality of life, and prolonged hospitalization. The purpose of this study was to
see if Colesevelam (Welchol) and Serum-derived bovine immunoglobulin-protein (SBI) result in
a change in the frequency or consistency of your bowel movements.